Synonyms: 26-hydroxycholesterol | 27-OHC
Compound class:
Metabolite
Comment: CID 99470 shows another representation of the stereochemistry of 27-hydroxycholesterol which is commonly reported in the literature.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Natural/Endogenous Targets | ||||
|
Selectivity at GPCRs | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
Selectivity at nuclear hormone receptors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Additional information and targets (data relate to human unless otherwise stated) | ||
Description | Data | Reference |
Potency order at Liver X receptor-α | 20S-hydroxycholesterol, 22R-hydroxycholesterol, 24(S)-hydroxycholesterol > 25-hydroxycholesterol, 27-hydroxycholesterol | 3 |
Potency order at Liver X receptor-β | 20S-hydroxycholesterol, 22R-hydroxycholesterol, 24(S)-hydroxycholesterol > 25-hydroxycholesterol, 27-hydroxycholesterol | 3 |
Targets where the ligand is described in the comment field | |
Target | Comment |
CYP27A1 | Converts cholesterol to 27-hydroxycholesterol. Autosomal-recessive mutations in CYP27A1 cause the bile acid metabolism disorder cerebrotendinous xanthomatosis (CTX, cerebral cholesterosis) [1,5]. An adenovirus vector encoding human CYP27A1 (VTX-806; Vivet Therapeutics) is being trialled as a gene replacement therapy for CTX. VTX-806 was granted Orphan Drug Designation by the EMA in September 2024 for this rare disease. |